H. R. 2820 

One Hundred Fourteenth Congress 

of the 

United States of America 

AT THE FIRST SESSION 

Begun and held at the City of Washington on Tuesday, 

the sixth day of January, two thousand and fifteen 

An Act 

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other 

purposes. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. SHORT TITLE. 

This Act may be cited as the ‘‘Stem Cell Therapeutic and 

Research Reauthorization Act of 2015’’. 

SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL 

TRANSPLANTATION PROGRAM. 

(a) IN GENERAL.—Section 379(d)(2)(B) of the Public Health 

Service Act (42 U.S.C. 274k(d)(2)(B)) is amended— 

(1) by striking ‘‘remote collection’’ and inserting ‘‘collection’’; 

and 

(2) by inserting ‘‘including remote collection,’’ after ‘‘cord 

blood units,’’. 

(b) AUTHORIZATION OF APPROPRIATIONS.—Section 379B of the 

Public Health Service Act (42 U.S.C. 274m) is amended— 

(1) by striking ‘‘$30,000,000 for each of fiscal years 2011 

through 2014 and’’; and 

(2) by inserting ‘‘and $30,000,000 for each of fiscal years 

2016 through 2020’’ before the period at the end. 

(c) SECRETARY REVIEW ON STATE OF SCIENCE.—The Secretary 

of Health and Human Services, in consultation with the Director 

of the National Institutes of Health, the Commissioner of the Food 

and Drug Administration, and the Administrator of the Health 

Resources and Services Administration, including the Advisory 

Council on Blood Stem Cell Transplantation established under section 379(a) of the Public Health Service Act (42 U.S.C. 274k(a)), 

and other stakeholders, where appropriate given relevant expertise, 

shall conduct a review of the state of the science of using adult 

stem cells and birthing tissues to develop new types of therapies 

for patients, for the purpose of considering the potential inclusion 

of such new types of therapies in the C.W. Bill Young Cell 

Transplantation Program (established under such section 379) in 

addition to the continuation of ongoing activities. Not later than 

June 30, 2019, the Secretary shall submit to the Committee on 

Health, Education, Labor, and Pensions of the Senate and the 

Committee on Energy and Commerce of the House of Representatives recommendations on the appropriateness of such new types 

of therapies for inclusion in the C.W. Bill Young Cell Transplantation Program. 
H. R. 2820—2 

SEC. 3. CORD BLOOD INVENTORY. 

Section 2 of the Stem Cell Therapeutic and Research Act of 

2005 (42 U.S.C. 274k note) is amended— 

(1) in subsection (a), by striking ‘‘one-time’’; 

(2) by striking subsection (c); 

(3) by redesignating subsections (d) through (h) as subsections (c) through (g), respectively; 

(4) in subsection (d) (as so redesignated)— 

(A) in paragraph (1), by striking ‘‘paragraphs (2) and 

(3)’’ and inserting ‘‘paragraphs (2), (3), and (4)’’; 

(B) in paragraph (2)(B), by striking ‘‘subsection (d)’’ 

and inserting ‘‘subsection (c)’’; and 

(C) by adding at the end the following: 

‘‘(4) CONSIDERATION OF BEST SCIENCE.—The Secretary shall 

take into consideration the best scientific information available 

in order to maximize the number of cord blood units available 

for transplant when entering into contracts under this section, 

or when extending a period of funding under such a contract 

under paragraph (2). 

‘‘(5) CONSIDERATION OF BANKED UNITS OF CORD BLOOD.— 

In extending contracts pursuant to paragraph (3), and determining new allocation amounts for the next contract period 

or contract extension for such cord blood bank, the Secretary 

shall take into account the number of cord blood units banked 

in the National Cord Blood Inventory by a cord blood bank 

during the previous contract period, in addition to consideration 

of the ability of such cord blood bank to increase the collection 

and maintenance of additional, genetically diverse cord blood 

units.’’; 

(5) in subsection (f) (as so redesignated)— 

(A) by striking paragraph (4); and 

(B) by redesignating paragraphs (5) and (6) as paragraphs (4) and (5), respectively; and 

(6) in subsection (g) (as so redesignated)— 

(A) in paragraph (1)— 

(i) by striking ‘‘$23,000,000 for each of fiscal years 

2011 through 2014 and’’; and 

(ii) by inserting ‘‘and $23,000,000 for each of fiscal 

years 2016 through 2020’’ before the period at the 

end; and 

(B) by striking paragraph (2). 
H. R. 2820—3 

SEC. 4. DETERMINATION ON THE DEFINITION OF HUMAN ORGAN. 

Not later than one year after the date of enactment of this 

Act, the Secretary of Health and Human Services shall issue determinations with respect to the inclusion of peripheral blood stem 

cells and umbilical cord blood in the definition of human organ. 

Speaker of the House of Representatives. 

Vice President of the United States and

President of the Senate.